Chen Weisong, Chen Hui, Zhu Dan, Luo Jianfeng, Ying Songmin, Deng Yincan, Yang Xiguang
Department of Respiratory Medicine, Jinhua Municipal Central Hospital, Jinhua, China.
Department of Respiratory Medicine, Jinhua Municipal Central Hospital, Jinhua, China -
Minerva Med. 2023 Apr;114(2):152-161. doi: 10.23736/S0026-4806.21.07188-3. Epub 2021 Mar 16.
The aim of this paper was to explore the application value of Stachys sieboldii Miq granules which is a kind of traditional Chinese medicine (TCM) in stable chronic obstructive pulmonary disease (COPD) patients.
Randomized double-blind method was used to select 160 patients with stable COPD. The patients were randomly divided into placebo group and Stachys sieboldii Miq group. Both groups underwent test items for 2 months, detected plasma cytokines, Saint George Respiratory Questionnaire (SGRQ) scores, pulmonary function, and the frequency of acute exacerbation (AE) at week 12. Follow-up was done every 12 weeks till 48 weeks to record the frequency of AE.
A total of 120 patients with 60 in each group were included. At week 12, there were significant differences in the plasma concentrations of TH17, IL-17A, IFN-γ and IL-10 between the two groups (all P=0.000). The proinflammatory factors TH17 and IL-17A were significantly lower in control group, while the anti-inflammatory factors IFN-γ and IL-10 were higher in the control group. And the SGRQ Score of Stachys sieboldii Miq group was significantly lower. There was no significant difference in lung function (FEV1, FVC, and FEV1/FVC) between the two groups (P=0.510, 0.529, and 0.843). Within 48 weeks, the AE frequency and change with time showed significant differences between the two groups (P=0.029), and the incidence of AE was reduced by 47.9% in Stachys sieboldii Miq group.
Stachys sieboldii Miq granules reduced proinflammatory factors and increased anti-inflammatory factors in stable COPD patients, reducing the probability of inducing AE treatment.
本文旨在探讨中药绵马贯众颗粒在稳定期慢性阻塞性肺疾病(COPD)患者中的应用价值。
采用随机双盲法选取160例稳定期COPD患者。将患者随机分为安慰剂组和绵马贯众组。两组均进行2个月的测试项目,在第12周时检测血浆细胞因子、圣乔治呼吸问卷(SGRQ)评分、肺功能及急性加重(AE)频率。每12周进行一次随访,直至48周,记录AE频率。
共纳入120例患者,每组60例。在第12周时,两组间TH17、IL-17A、IFN-γ和IL-10的血浆浓度存在显著差异(均P = 0.000)。促炎因子TH17和IL-17A在对照组显著降低,而抗炎因子IFN-γ和IL-10在对照组较高。且绵马贯众组的SGRQ评分显著更低。两组间肺功能(FEV1、FVC和FEV1/FVC)无显著差异(P = 0.510、0.529和0.843)。在48周内,两组间AE频率及随时间的变化存在显著差异(P = 0.029),绵马贯众组AE发生率降低了47.9%。
绵马贯众颗粒可降低稳定期COPD患者体内的促炎因子,增加抗炎因子,降低诱发AE的治疗概率。